UBS: lowered Ali's health rating to neutral and lowered the target price to HK $7.8
Financial Associated Press, Dec. 18 (Reuters) - UBS issued a report to update its financial forecast for Ali health, downgraded its share rating from buy to neutral, and lowered its target price from HK $26 to HK $7.8.
This text is a result of machine translation.
Related companies：
Briefing Feb 21, 2023 11:10 AM
· Healthcare
We-Linking Raised Over CNY 10 Mn in Angel Round
Briefing Feb 21, 2023 10:07 AM
· Healthcare
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
In-depth
Briefing Feb 16, 2023 12:51 PM
· Healthcare
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
Briefing Feb 15, 2023 12:32 PM
· Healthcare
ZD Medtech Raised Over CNY 100 Mn in Series B
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 18, 2022 06:30 PM
Briefing Feb 13, 2023 12:54 PM
· Healthcare
Smart Powered Bionic Prosthetic Star BionicM Nets Over CNY 10 Mn
Briefing Oct 15, 2021 05:24 PM
· Healthcare
New drugs will be on the shelves in three days at the fastest, and Ali health pharmacy starts the "new drug launch support plan"
Briefing Aug 04, 2021 10:14 AM
· Healthcare
Hong Kong stocks Ali concept stocks strengthened. Ali health rose 5.1%
In-depth
Briefing Jul 23, 2020 10:50 AM
· Healthcare
Health Monitor App Xiyou Closes Series A to Build New Pharma Retail Ecosystem
Briefing Jul 21, 2020 05:56 PM
· Healthcare
Wider Health Insurance Coverage Benefits Online Healthcare Business
Briefing Jul 20, 2020 10:52 AM
· Healthcare
Ali Health Denies Alibaba Selling Shares Rumor
See more
Read next
Insight
In-depth
Insight
In-depth